Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-arrestin2 siRNA
- Development stage
- Preclinical
- Lead developer
- Duke University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
beta-arrestin2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the *ARRB2* gene, which encodes the beta-arrestin 2 protein. Beta-arrestin 2 is a multifunctional adaptor protein traditionally known for its role in the desensitization and internalization of G-protein-coupled receptors (GPCRs). In the context of oncology, specifically multiple myeloma (MM), beta-arrestin 2 has been identified as a potential therapeutic target due to its correlation with poor clinical outcomes and resistance to proteasome inhibitors like bortezomib. Preclinical research, such as that presented at ASH 2024, indicates that knockdown of beta-arrestin 2 using siRNA can down-regulate the expression of immune checkpoints, including PD-1 in T cells and PD-L1 in myeloid-derived suppressor cells (MDSCs), thereby potentially enhancing anti-tumor immune responses within the bone marrow microenvironment.
- Other names
- β-arrestin2 siRNAArrb2 siRNAArrb-2 siRNAArrb 2 siRNAbeta-arrestin 2 siRNAbeta-arrestin2 siRNAbeta-arrestin-2 siRNAβarr2 siRNA
02
Targets
ARRB2 (Beta-arrestin-2)
Beyond the preview
Go deeper on beta-arrestin2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-arrestin2 siRNA.